Merck + Co., Inc.

Sebastian Hernandez

Robert T Goegelman

Edward O Stapley

Frederick M Kahan

Jean S Kahan

Patrick J Cassidy

Sheldon B Zimmerman

Richard W Burg

Otto D Hensens

Jerrold M Liesch

Lucille J Cole

Josefino B Tunac

Leeyuan Huang

George E Albers-Schonberg

Louis Chaiet

Vincent P Gullo

Ray S Dewey

There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compounds structures are presented based upon analytical studies. The compounds have antifungal activity.

Antifungal substances and process for their production

There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compounds' structures are present based upon analytical studies. The compounds have antifungal activity.

Novel antifungal substances and process for their production

There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compound's structure is presented based upon analytical studies. The compound has antifungal activity.

There is disclosed a macrolide isolated from the fermentation broth of a microorganism identified as MA-5285 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compound's structure is presented based upon analytical studies. The compound has insecticidal and antiparasitic activity.

Substance and process for its production

There is disclosed a novel series of compounds isolated from the fermentation broth of a strain of the microorganism Streptomyces sp MA5038. The compounds have a 16-membered macrocyclic lactone structure with various substituents thereon. The compounds have insecticidal and antitapeworm activity and compositions for such uses are disclosed.

Novel substances and process for their production

The antibiotic MSD A63A, having antibacterial and growth-permittant activity, is produced by fermentation of Streptoverticillum hiroshimense MA4845 (ATCC 31586), in a suitable nutrient media.

Discovery of MSD A63A, a new efrotomycin-line antibiotic fermentation

The antibiotic thienamycin is active against both gram-positive and gram-negative bacteria. The antibiotic is produced by growing a newly-found and hitherto undescribed species of Streptomyces on suitable fermentation media.

Culture of Streptomyces cattleya

The antibiotic MSD 890A.sub.10 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotic 890A.sub.10) is active against both gram-positive and gram-negative bacteria. The antibiotic is produced by growing species of Streptomyces on suitable fermentation media.

Antibiotic 890A.sub.10

The antibiotic MSD 890A.sub.9 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotic 890A.sub.9) is active against both gram-positive and gram-negative bacteria. The antibiotic is produced by growing species of Streptomyces on suitable fermentation media.

Method of producing antibiotic 890A.sub.9

The antibiotics MSD 890A.sub.1 and MSD 890A.sub.3 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotics 890A.sub.1 and 890A.sub.3) are active against both gram-positive and gram-negative bacteria. The antibiotics are produced by growing species of Streptomyces on suitable fermentation media.

Process for producing antibiotics by cultivation of Streptomyces

The antibiotic N-acetyl thienamycin and its non-toxic pharmaceutically acceptable salts are active against both gram-positive and gram-negative bacteria. The antiobiotic is produced by growing a species of Streptomyces on suitable fermentation media or alternatively by acetylation of thienamycin.

Acetylthienamycin production

The antibiotics MSD 890A.sub.2 and MSD 890A.sub.5 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotics 890A.sub.2 and 890A.sub.5) are active against both gram-positive and gram-negative bacteria. The antibiotics are produced by growing species of Streptomyces on suitable fermentation media.

Process for producing antibiotics

The antibiotic N-acetyl thienamycin and its non-toxic pharmaceutically acceptable salts are active against both gram-positive and gram-negative bacteria. The antibiotic is produced by growing a species of Streptomyces on suitable fermentation media or alternatively by acetylation of thienamycin.

Growing community of inventors

Madrid, Spain

Sebastian Hernandez